Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT07258979

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

A Multicenter, Open-label, Phase Ib/II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 Combined With Toripalimab, With or Without Cisplatin, in Subjects With Recurrent or Metastatic Nasopharyngeal Carcinoma.

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Conditions Recurrent or Metastatic Nasopharyngeal Carcinoma

Interventions Cisplatin Toripalimab YL201

Updated 1 time since 2026 Last updated: Nov 21, 2025 Started: Nov 5, 2025 Primary completion: Feb 29, 2028 Completion: May 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07258979, this PHASE1/PHASE2 trial focuses on Recurrent or Metastatic Nasopharyngeal Carcinoma and remains actively recruiting participants. Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd., it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

1 version recorded

Recruiting — PHASE1/PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MediLink Therapeutics (Suzhou) Co., Ltd.

Data source: MediLink Therapeutics (Suzhou) Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Changsha, China , Chengdu, China , Chongqing, China , Dongguan, China , Fuzhou, China , Guangzhou, China , Guilin, China , Haikou, China , Hangzhou, China , Jiangmen, China and 7 more locations